Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
No PRAME encore for Immatics
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
Immatics’ PRAME gift keeps on giving
The company dribbles out more data on IMA203, and the numbers head in the right direction.
Immatics builds on its PRAME success
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.
